Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

JOURNAL ARTICLE published February 2010 in Bone Marrow Transplantation

Authors: M Lioznov | J El-Cheikh | F Hoffmann | Y Hildebrandt | F Ayuk | C Wolschke | D Atanackovic | G Schilling | A Badbaran | U Bacher | B Fehse | A R Zander | D Blaise | M Mohty | N Kröger